WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 33.06
+0.40 (1.22%)
May 11, 2026, 4:08 PM HKT
WuXi Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
Depreciation & Amortization | 1,448 | 1,437 | 1,169 | 800.67 | 481.78 |
Other Amortization | 29.98 | 24.43 | -73.88 | 32.36 | 90.49 |
Loss (Gain) From Sale of Assets | 634.68 | -0.46 | 3.48 | 19.27 | 0.87 |
Loss (Gain) From Sale of Investments | -1,045 | 91.72 | -13.83 | -379.44 | -665.44 |
Stock-Based Compensation | 955.06 | 1,216 | 1,274 | 1,234 | 531.92 |
Provision & Write-off of Bad Debts | 205.33 | 151.78 | 319.97 | 258.53 | 156.67 |
Other Operating Activities | 935.66 | -258.43 | -514.84 | 130.08 | 409.82 |
Change in Accounts Receivable | -2,590 | 161.93 | -1,038 | -1,500 | -1,441 |
Change in Inventory | 6.39 | 201.85 | 442.46 | -498.12 | -783.19 |
Change in Accounts Payable | 797.37 | 375.38 | -162.34 | -509.02 | 741.85 |
Change in Unearned Revenue | 410.38 | -1,313 | -317.2 | 1,633 | 1,071 |
Change in Other Net Operating Assets | -355.53 | -226.69 | 178.41 | -100.14 | -551.77 |
Operating Cash Flow | 6,341 | 5,217 | 4,668 | 5,542 | 3,431 |
Operating Cash Flow Growth | 21.54% | 11.77% | -15.77% | 61.51% | 82.39% |
Capital Expenditures | -3,685 | -3,930 | -4,046 | -5,868 | -6,508 |
Sale of Property, Plant & Equipment | 4,177 | 87.33 | 196.86 | 20.13 | 80.86 |
Cash Acquisitions | - | - | - | -131.49 | -2,181 |
Sale (Purchase) of Intangibles | -50.6 | - | -10 | - | - |
Investment in Securities | -3,952 | -387.97 | 596.39 | -253.24 | -1,428 |
Other Investing Activities | 423.07 | 288.56 | 34.07 | 324.74 | 433.9 |
Investing Cash Flow | -3,087 | -3,942 | -3,228 | -5,908 | -9,602 |
Long-Term Debt Issued | 1,122 | 1,129 | 1,097 | 2,389 | 675.28 |
Total Debt Issued | 1,122 | 1,129 | 1,097 | 2,389 | 675.28 |
Long-Term Debt Repaid | -2,901 | -818.68 | -1,916 | -2,684 | -822.11 |
Total Debt Repaid | -2,901 | -818.68 | -1,916 | -2,684 | -822.11 |
Net Debt Issued (Repaid) | -1,779 | 309.96 | -818.45 | -295.02 | -146.83 |
Issuance of Common Stock | 163.07 | 19.39 | 26.16 | 36.18 | 11,035 |
Repurchase of Common Stock | -1,577 | -1,766 | -916.92 | -2,804 | -2,517 |
Other Financing Activities | 1,029 | -1,314 | 3,670 | 471.7 | -161.91 |
Financing Cash Flow | -2,164 | -2,750 | 1,961 | -2,592 | 8,209 |
Foreign Exchange Rate Adjustments | -155.21 | 83.98 | -125.99 | 350.11 | -131.5 |
Net Cash Flow | 934.6 | -1,391 | 3,275 | -2,608 | 1,908 |
Free Cash Flow | 2,656 | 1,288 | 622.14 | -326.72 | -3,077 |
Free Cash Flow Growth | 106.25% | 106.97% | - | - | - |
Free Cash Flow Margin | 12.19% | 6.89% | 3.65% | -2.14% | -29.90% |
Free Cash Flow Per Share | 0.64 | 0.30 | 0.14 | -0.07 | -0.70 |
Cash Interest Paid | 159.57 | 200.61 | 217.28 | 108.24 | 83.2 |
Cash Income Tax Paid | 1,400 | 1,092 | 782.53 | 585.66 | 349.99 |
Levered Free Cash Flow | 4,284 | -2,296 | -320.31 | -594.39 | -3,720 |
Unlevered Free Cash Flow | 4,373 | -2,198 | -221.25 | -554.16 | -3,696 |
Change in Working Capital | -1,731 | -800.5 | -896.35 | -974.47 | -963.33 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.